INDEX BRAZILIAN PHARMA SOLUTIONS.........................................................................................................................03 ABIQUIFI..............................................................................................................................................................................04 APEX-BRASIL ...................................................................................................................................................................05 PARTNERS...........................................................................................................................................................................06 BIO-MANGUINHOS / FIOCRUZ...............................................................................................................................07 BUTANTAN .......................................................................................................................................................................08 CNI ........................................................................................................................................................................................09 INDI ......................................................................................................................................................................................10 LIBBS .................................................................................................................................................................................... 11 ADESTE..................................................................................................................................................................................12 AMBIOTEC.............................................................................................................................................................................................12 AXIS BIOTEC ........................................................................................................................................................................................12 BIOCAD...................................................................................................................................................................................................13 BIOCLIN .................................................................................................................................................................................................13 BIOLAB.....................................................................................................................................................................................................14 BIOLOTUS .............................................................................................................................................................................................14 BIOMINAS .............................................................................................................................................................................................14 BIOMM ...................................................................................................................................................................................................15 BIONOVIS ..............................................................................................................................................................................................15 BIOTÉCNICA ........................................................................................................................................................................................15 BIOZEUS..................................................................................................................................................................................................16 BCO............................................................................................................................................................................................................16 BRASTERÁPICA ..................................................................................................................................................................................16 CELER ......................................................................................................................................................................................................17 FARMA CORE ......................................................................................................................................................................................17 FLUXIS .....................................................................................................................................................................................................17 GENTROS ..............................................................................................................................................................................................17 GUSMÃO & LABRUNE ....................................................................................................................................................................18 INSTITUTO VITAL BRASIL . ............................................................................................................................................................18 INVITRO .................................................................................................................................................................................................18 JHS.............................................................................................................................................................................................................19 KASZNAR LEONARDOS ................................................................................................................................................................19 LINHAGEN..............................................................................................................................................................................................19 ORYGEN .................................................................................................................................................................................................19 OURO FINO...........................................................................................................................................................................................20 RECEPTA ................................................................................................................................................................................................20 SUPERA....................................................................................................................................................................................................21 VERITAS ..................................................................................................................................................................................................21 VISIONGEN............................................................................................................................................................................................21
2
THE PROJECT – BRAZILIAN PHARMA SOLUTIONS The Brazilian Pharmachemical Industry Association (Abiquifi) and the Brazilian Trade and Investment Promotion Agency (Apex-Brasil) develop, in partnership, the project of the internationalization of pharmachemical and pharmaceutical brazilian sectors. They also have the support of other industry organizations as Sindusfarma, Alanac, Interfarma, Pró-Genericos and Abifina. The initiative aims to expand the participation of companies from Brazilian pharmaceutical and pharmachemical productive chain into the international scenario, seeking to increase exports, exchange of technology, attraction of investments and internationalization of the sector. It promotes actions in business intelligence, international marketing, prospective missions, building export capacity, international fairs, business rounds and trade missions directed to different target markets, including countries from all five continents. FURTHER INFORMATION: atendimento_psi@abiquifi.org.br + 55 (11) 2638-4487 / 4519
3
ABIQUIFI The Brazilian Association of Pharmaceutical Ingredients Producers (Abiquifi) is a nonprofit company founded in 1983 and brings together companies from the pharmachemical and pharmaceutical inputs’ sector. Its main goal is stimulate the development of their production in Brazil. Abiquifi has its own website on the internet (www.abiquifi.org.br) with various market information, statistics, relevant laws and many other important data; it publishes an annual index which records all pharmachemicals and pharmaceutical inputs produced in Mercosur, besides coordinating the project of internationalization of the sector. abiquifi@abiquifi.org.br +55 21 2220-3005
4
ABOUT APEX-BRASIL The mission of the Brazilian Trade and Investment Promotion Agency (Apex- Brasil) is to foster the competitiveness of Brazilian companies by promoting their internationalization and the attraction of foreign direct investment (FDI) into Brazil. Apex-Brasil currently supports about 13,000 companies from 81 sectors of the Brazilian economy, which export to more than 200 markets. In partnership with sector associations, the Agency organizes trade promotion initiatives, such as prospective and trade missions, business rounds, support to the participation of Brazilian companies in major international fairs and customized tours to foreign buyers and opinion-makers introducing them to the Brazilian productive structure. Apex- Brasil also releases business and competitive intelligence studies which play a critical role in the decision of Brazilian companies to enter the international market. Besides its headquarters in Brasilia, Apex-Brasil has Desks in Brazilian states and Business Support Centers (BSCs) around the world. These BSCs serve as platforms to assist Brazilian companies in expanding their businesses to global markets, to explore new business opportunities, to increase Brazil’s market share in key global markets, and to serve as a benchmark for foreign investment attraction. BSCs are strategically located in Asia (Beijing China), Middle East (Dubai - United Arab Emirates), North America (Miami - USA), Central America and the Caribbean (Havana Cuba), Western Europe (Brussels - Belgium), Eastern Europe (Moscow - Russia) and Africa (Luanda - Angola). Next to the Brussels BSC is the Brazilian Business Affairs (BBA), an Apex-Brasil office established to monitor trends and decisions of the European Union that may affect Brazilian exports. Apex-Brasil plays a leading role in attracting foreign direct investment (FDI) into Brazil, working to identify business opportunities, promoting strategic events and lending support to foreign investors willing to allocate resources in Brazil. The aim is to attract productive capital from foreign companies that may introduce technological innovations and new business management models into Brazil and to strengthen supply chains. apexbrasil@apexbrasil.com.br +55 61 3426-0202
5
PARTNERS
Abifina Brazilian Fine chemicals industries, biotechnology and Specialties Association www.abifina.org.br
Alanac National Pharmaceutical Laboratories Association www.alanac.org.br
Interfarma National Pharmaceutical Laboratories Association www.interfarma.org.br
Pro Genéricos Brazilian Generic Medicines Industry Association www.progenericos.org.br
Sindusfarma São Paulo State’s Pharmaceutical Industry Business Association www.sindusfarma.org.br
6
The Immunobiological Technology Institute (BioManguinhos) - founded in 1976 – is the biggest andmost modern federal laboratory for R&D and production of immunobiologicals and IVD reagents in Brazil. This technical-scientific unit of the Oswaldo Cruz Foundation (Fiocruz) plays a strategic role in the supplying of a range of pediatric vaccines for around 3.5 million of newborns per year, besides biopharmaceuticals and IVD reagents, mostly for the Brazilian public health system. Bio-Manguinhos presents high performance in the production sector, as well as in research and development aiming to create new products and technologies, knowledge and economic benefits to the country. Besides the autochthonous development with a high skilled team, the Institute has a vast experience with national and global partnerships for co-development and technological transfer processes. To boost its capacity to respond to demands from the Ministry of Health, the Institute has been expanding its infrastructure. Bio-Manguinhos will occupy a large area in the western zone of Rio de Janeiro and another one in Ceará, for a total combined area of 763,500m². PortfolioVaccines - Diphtheria, Tetanus, Pertussis and Haemophilus influenzae type b •Haemophilus influenzae type b • Measles, Mumps and Rubella • Measles, Mumps, Rubella and Varicella • Oral Poliomyelitis • Inactivated Poliomyelitis • Rotavirus • 10-valent Pneumococcal • Polysaccharide Men AC • Yellow Fever IVD Reagents - NAT HIV/HCV • Imunoblot DPP® HIV-1/2 • DPP® HIV-1/2 • DPP® Syphilis • DPP® Canine Leishmaniasis • DPP®Leptospirosis • Chagas Disease IFA • Canine Leishmaniasis ELISA and IFA • Human Leishmaniasis IFA • Helm Test Biopharmaceuticals - Interferon alpha 2b • ErythropoietinCore businessVaccines: Prokaryotic expression • Eukaryotic expression • Conjugation • Plant based IVD Reagents: Rapid Tests • Flow Cytometry • Microarrays • Molecular Assays Biopharmaceuticals: Monoclonal Antibodies • Therapeutic Proteins
MISSION To contribute to public health through research, innovation, production and development of biological products, sharing knowledge with the society. VISION To be a world-class public institution dedicated to research, development, dissemination, education, and the manufacturing of biological products for public health demands PRODUCTS Vaccines DTP Diphtheria-Tetanus-Pertussis (celular) ∙ dT Diphtheria-Tetanus (for adults) DT ∙ Diphtheria-Tetanus (for children) ∙ Rabies ∙ Hepatitis B ∙ Influenza Serums 5 Snake Antivenoms ∙ Spider Antivenom ∙ Scorpion Antivenom ∙ Caterpillar Antivenom ∙ Diphtheria Antitoxin ∙ Tetanus Antitoxin ∙ Botulism AB Antitoxin ∙ Botulism E Antitoxin ∙ Rabies Antiviral Pipeline Dengue Vaccine ∙ Rotavirus Vaccine ∙ Pertussis low Vaccine ∙ Pneumococcal Vaccine ∙ DTPlow+HepB+Hib Vaccine ∙ DTPlow+HepB+Hib+IPV+MenC Vaccine ∙ Hepatitis B + MPLA Vaccine ∙ rBCG + Hep B Vaccine ∙ Onco rBCG Vaccine ∙ Adjuvant BpMPLA ∙ Bee’s Antivenom ∙ Sílica (SBA-15) ∙ Amblyomin-X ∙ Crotalphine ∙ Crotamin ∙ Lopap ∙ Monoclonal antibodies ∙ Hemoderivatives Founded in 1901, the Instituto Butantan is an outstanding center of biomedical investigation engaged in scientific and technological research, production of immunobiological products and dissemination of technicalscientific information, constantly aiming at the update and integration of its resources and innovations. Instituto Butantan is the main producer of immunobiological products in Brazil. As such, it is responsible for a large percentage of the domestic production of hyperimmune serums and a great volume of the vaccine antigens made in Brazil that go into vaccines used by the Ministry of Health’s National Immunization Program, PNI. The technological development activities related to the production of health products are associated with the creation of vaccines, serums and biopharmaceuticals for human use. The institute’s main mission, therefore, is to meet the demands fundamentally focused on public health, contributing to the continuous effort of providing for the welfare of the population. Along with its research, r&d and production activities, Butantan also offers an MBA in Health Innovation Management, a Graduate Toxinology program and many extension and short-term finishing courses, as well as educational and cultural activities in its four museums. Butantan carries out scientific missions in the country and abroad through the Pan American Health Organization, the World Health Organization, UNICEF and the United Nations. It collaborates with other agencies of the São Paulo State Secretariat for Health and the Brazilian Ministry of Health for the improvement of overall health. It acts in partnership with various universities and entities such as the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation, for the achievement of its institutional objectives. Instituto Butantan Av. Vital Brasil, 1500, Butantã, 05503-900 São Paulo, SP, Brazil, +55 11 2627-9507 diretoria.secretaria@butantan.gov.br - www.butantan.gov.br
The Brazilian National Confederation of Industry (CNI) is the largest and highestlevel representation of industry in Brazil with a mission to promote a favorable business environment, enhancing companies’ competitiveness and promoting sustainable development in Brazil. CNI represents and coordinates 27 state federations of industry, over 200.000 enterprises, encompassing issues such as: economic policy, infrastructure, environment, SME development, labor relations, social responsibility, inovation and international affairs. CNI´s BIOECONOMY – An Agenda for Brazil. In 2013 CNI lunched its Agenda for Bioeconomy, its main aim and priorities to set up a vibrant bioeconomy sector in Brazil are: • Take the advantage of Brazil being the most megabiodiverse country in the world; • Modernize and advance the regulatory framework towards a pro-science, pro-innovation and pro-production aproaches; • Generate a critical mass of qualified researchers; • Promote the creation and enlarge multidisciplinary groups with researcher-entrepreneurinnovator profile; • Reinforce and expand the laboratory infrastructure; • Provide lift-off for a still fragile base of entrepreneurial and innovative scientists and technologists. • Remove the barriers that prevent scientific and technological knowledge from being transferred from academia to companies. • Disseminate knowledge about strategies of protection and management of intellectual property, specially about patents; • Respect principles of sustainability and conservation of natural resources, as well as the guarantee that domestic industry can compete in the global market. The sectors covered by the bioeconomy differ from the more traditional ones, since human capital and knowledge are the key of the frontiers of science, where new companies and
bioeconomia@cni.org.br www.portaldaindustria.com.br/cni/canal/bioeconomia/
The Integrated Development Institute of Minas Gerais (INDI) was founded in 1968 with the mission of developing the State’s industrial sector. The aim of the institution was to spark the interest of potential domestic and foreign investors to the potential or comparative advantages that the State would have in relation to other regions of Brazil. It was an institution that was concerned with the preparation of studies in search of opportunities for industrialization of the state. During the 70s, the contribution of INDI was essential for the modernization and diversification of the state economy. New companies emerged from the electronics, automotive, chemicals and fertilizers sectors. In the ’80s, with the unfolding of the second oil shock, INDI worked in the search for new alternatives to deal with the problems that affected the entire world economy. It participated in studies that enabled the import substitution of the industry in Minas Gerais. In the 90s, exports were encouraged by the openness of the Brazilian economy and as a consequence the number of foreign companies investing in Brazil increased, and consequently in Minas Gerais. In the 2000s, the INDI’s name was changed from Industrial Development Institute for Integrated Development Institute, starting to work on projects that transcend the strictly industrial activity. In 2014, INDI completes 46 years of existence, which consolidates the institute as one of the most traditional investment promotion agencies in the country. INDI provides various services to entrepreneurs, who want to set up production units in Minas Gerais and supports enterprises which are already established in the State, assisting them in the process of expansion, relocation and expansion of competitiveness. All work developed by INDI is carried out at no cost for investors.
Contact: Valéria Dias valeriad@indi.mg.gov.br +55 31 3915-2873 www.indi.mg.gov.br
It´s how we treat life
Daniel Oelsner Lopes daniel.oelsner@adeste.com.br www.adeste.com.br Adeste Pharma is the healthcare division of Adeste Group, a Brazilian conglomerate with more than 65 years and businesses in the Food, Healthcare, Pet and Cables industries. Adeste Pharma is the main provider in Latin America of bovine and porcine Heparin API, Chondroitin Sulfate API, FBS (Fetal Bovine Serum) and Catgut threads for Sutures. Our healthcare division guarantees the quality of our products through a comprehensive control of our processes and the strict traceability in our production system. Availability, Safety and Traceability make Adeste Pharma your first choice.
Vanessa Silva vanessasilva@ambiotec.org.br www.ambiotec.org.br AMBIOTEC – Minas Gerais Bioindustry Association is a private and nonprofit organization, representing companies of Biotechnology and Life Sciences in Minas Gerais State, in Brazil. The Biotech Cluster in Minas Gerais plays an important role in the brazilian bioindustry with 200 biotech companies working in the fields of human health, animal health, environment and agribusiness. The main products and services include the diagnostic kits and reagents for clinical analysis, molecular diagnostics, plant genetic breeding, laboratory control, biomaterials, regenerative medicine, automation equipments, medical devices and hospital equipments.The AMBIOTEC offers representation to member companies and business support through management programs, quality management and certification, trade promotion in international fairs, prospective and trade missions, business rounds and other opportunities.
Ana Monteiro ana.monteiro@axisbiotec.com.br www.axisbiotec.com.br Axis Biotec Brasil is a holding company that sponsors and manages research, development and innovative business in the health and life sectors. With strong expertise in R&D, and also in sales and marketing, over the last 30 years, the companies of the group have been successful in translating research into innovative products and services in the health sector. Today, Axis Biotec is the major shareholder in four companies in Brazil: Silvestre Labs (pharmaceutical company), Cryopraxis (long-term biological material cryogenic bank), CellPraxis (bioengineering company focused in regenerative medicine and cell therapy) and PharmaPraxis (biopharmaceutical corporation). These companies directly employ over 200 professionals and involve another 500 in various projects. 12
BRASIL
Dr. David Zylbergeld Neto david.zylbergeld@biocadbrazil.com.br www.biocadbrazil.com.br
Biocad Monoclonal is a consortium formed with the union of Laboratório Daudt, a Pharmaceutical Laboratory with 134 years of existence, situated in Rio de Janeiro and BiocadBrazil Farmacêutica located in São Paulo. The objective of this consortium is to establish Productive Development Partnerships (PDP) with the Brazilian Government once there is a State Policy aimed at internalizing the entire production process of biological drugs, which includes, of course, the active ingredients. Biocad Monoclonal is totally aligned with this scope and has applied 3 development productive partnerships (PDP) so far, through its partnership with TECPAR – A Brazilian Public Laboratory located in the State of Paraná. Biocad Monoclonal is very glad to say that got the Brazilian Ministry of Health approval in its first PDP application for bevacizumab. The other 2 applications were delivered successfully and are being currently analyzed by the Brazilian Government. In long-term the consortium has an ambitious goal that is to build a plant of biological products within the national territory, ensuring greater access for patients to the highly complex medicines, as well as become a distributor pole within Latin America. Since its origin, Biocad Monoclonal has been engaged with great ethics and professionalism in the development of PDPs. The company has done an excellent job on all fronts necessary for the success of the PDP project: Institutional, Legal and Technical. The successful implementation of this PDP project will strengthen excellence in biotechnology and scientific knowhow, consolidating an expansion project in Latin America for the active pharmaceutical ingredients and finished dosage forms.
Silvio Arndt silvioarndt@bioclin.com.br www.bioclin.com.br Bioclin is a trademark of Quibasa. We are a Brazilian company dedicated to the development and manufacturing of in vitro diagnostic tests and reagents for clinical laboratories since 1977. We have a net of distributors around Brazil and in all counties of South America. We are a certificated company for ISO 13485, ISO 9001, ANVISA`s GMP and ANVISA`s Good Distribution and Storage Practices. We have more than 100 products with the CE mark.
13
Bruna Alario
balario@biolabfarma.com.br www.biolabfarma.com.br
Biolab is a privately owned Brazilian pharmaceutical company, among the Top 10 on the ethical market, focused on prescription drugs, leader in cardiology, with strong internal R&D activity and partnerships. With over 100 products on its portfolio, it reached 1B (BRL) on sales revenue in 2014.
Jo達o Transmontano jtransmontano@biolotus.com ; biolotus@biolotus.com www.biolotus.com Biolotus Biotech is a pharmaceutical company specializing in R&D, registration, manufacture, promotion and worldwide distribution of pharmaceutical products of biotechnology origin. Biolotus Biotech manufactures its products in Asia and Europe and plans to develop and manufacture a new generation of biological products in Brazil. Biolotus Biotech has currently research cooperation projects with several entities to develop new products and welcomes new partnerships. Our mission is To Serve!
Arthur Nigri arthur@biominas.org.br www.biominas.org.br Biominas Brasil is a private institution established in 1990 and specialized in promoting business opportunities in the Brazilian life sciences industry. Biominas supports national and international research projects, companies and investors at all stages of development, through a variety of services including Consulting, Business Development and Incubation. Biominas also publishes studies and organizes business events for the life sciences sector, such as the BIO Latin America Conference. Our exclusive focus on life sciences, our in-depth knowledge of the sector and our broad network of contacts make Biominas your ideal partner for developing a successful life sciences business.
14
Douglas Lopes douglas.lopes@biomm.com www.biomm.com Biomm is a company resulting from the spin-off of Biobrás, a pioneering player in pharmaceutical biotechnology in Brazil. It is a publicly held corporation with stocks traded at BOVESPA+ Stock Exchange (BIOM3). 15 The company is building a state-of-the-art biopharmaceutical plant in Minas Gerais to manufacture insulin products and other biosimilars using a technological platform developed in Brazil and patented in the USA, Europe and Asian countries. With track record of more than 30 years, a high quality innovative team and a capital structure that enables Biomm to advance in different projects, Biomm is your ideal partner for biopharmaceuticals in Brazil.
Odnir Finotti contact@bionovis.com.br www.bionovis.com.br Bionovis is a biopharmaceutical joint venture composed of four major Brazilian pharmaceutical players: Aché, EMS, Hypermarcas and União Química. Together, Bionovis´ shareholders hold almost 33% of the Brazilian pharmaceutical market in units and 28% in value with a total of US$ 7.3 bi sales. Bionovis is engaged in R&D, manufacturing and marketing of biotech medicines, with a pipeline composed of biosimilars, biobetters and innovative molecules. Bionovis is presently building a state-of-the-art industrial plant to manufacture monoclonal antibodies and other biopharmaceuticals. The company is open to discuss inlicensing, technology transfer, partnering and/or co-development of products from early development to clinical stages.
Marcelo H. Rocha comercial@biotecnicaltda.com.br www.biotecnica.ind.br BioTécnica is dedicated to the research, production and trade of reagents and equipment for In Vitro Diagnostic Use. Operating since 2000, Biotecnica is located in Varginha, city in the south of Minas Gerais, Brazil. It currently works with an infrastructure of more than ten thousand square meters and several employees with high technical and managerial competence. The company has been highlighted in the National diagnostic market, based always on developments with balance, respect for people and teamwork.
15
Luis Eduardo Caroli caroli@biozeus.com.br www.biozeus.com.br BioZeus is a Brazilian biopharmaceutical company totally focused on identifying innovations from Brazilian universities and research institutes and to advance and derisk these compounds until proof of clinical concept. With a decentralized company model and an experienced team of national and international experts, BioZeus is able to advance projects with more speed, reduced risk in a more cost effective manner than traditional start-ups.
Marco Aurelio Braga braga@bcoa.com.br www.bcolaw.com.br Braga, Carvalho & Octaviani Law Firm – BCO Law, is specialized in Economic Law, providing legal advisory in areas such as environmental law, regulatory affairs regarding the biotech industry and Intellectual Property. Formed by lawyers with dynamic and distinguished careers, BCO Law prioritizes constant attention and dedication to its clients. Our lawyers are committed to ally proximity and technical quality in order to provide precise answers and excellent results to their clients.
Adriana Schulz dos Santos adriana@brasterapica.com.br www.brasterapica.com.br Completing four decades in 2014, Brasterápica Pharmaceuticals is a 100% domestic capital drug industry, headquartered in Atibaia, São Paulo. On the national level, its portfolio offers quality drugs at affordable prices. Since its founding in 1974, constantly striving to maintain and expand their position earned in the competitive pharmaceutical market, it operates in the manufacturing of drugs, with leading brands along the lines of Over-the-Counter Drugs (OTC), Herbal Remedies, Pharmaceuticals, Dietary Supplements, Generics and Hospital Medications. The trust and credibility in our brands are the result of rigorous industrial standards followed in respect to the consumer and in compliance with rules established and enforced by ANVISA. With conduct being allied with environmental responsibility and certifications, Brasterápica is in search of solutions and constant improvements in their production processes, monitoring waste disposal and recycling. Having as a basis for the success and longevity, ethics and flexibility in their partnering business relations, Brasterápica stimulates proximity and flexibility in their care, in an authentic and transparent manner. Our principle is to provide, with simplicity, quality of life and well being to human beings, respecting the world in which we live in. 16
Denilson Laudares Rodrigues denilsonlr@celer.ind.br www.celer.ind.br Celer has all registrations at ANVISA to produces and distributes instruments and consumables (reagents) for IVD. Come to Brazil with Celer!
Helena Faccioli Lopes helena@farmacore.com.br www.farmacore.com.br Farmacore is a biotech company that develops and improves value in innovative biotechnological products during all stages, since conception of projects, to supply of active pharmaceutical ingredients (immunobiologicals) specially for the veterinary sector. As a CMO, Farmacore owns technologically advanced Bioprocess Facilities allowing the production of a wide range of plasmid needs, permitting the lowest cost of production and highest product quality, especially in GMP regulated environments. As a CRO, the company offers a complete and integrated range of services to pharmaceutical and veterinary companies, and public or private research centres, helping its clients to find practical solutions for their products development in a short time.
Sandro Moraes sandro.cdm@gmail.com www.fluxis.com.br Fluxis is a full solution to manage your company that integrate product data management (PDM), enterprise resource planning (ERP) and customer relationship management (CRM) in unique platform. The perfect tool for medical device, bio-science company. To become the best option for the product management our solution was developed focused on the product life cycle and processes derived by it. The Fluxis support the QMS implementation with flexibility to be in conformance for ISO9001, ISO13485 and Good Manufacture Practice (GMP). Taila Lemos, MS, PhD, MBA taila.lemos@gentros.com.br www.gentros.com.br Gentros is a biotechnology company that develops product and customized service based in recombinant protein and microbime. In its seven years, Gentros has developed three recombinant vaccines and provided services in the microbiome for several large corporations of cosmetic and human heath sectors. 17
Ana Paula Celidônio acelidonio@glpi.com.br www.glpi.com.br Gusmão & Labrunie is a law firm based in São Paulo, Brazil. It was founded in 1988 and since then we specialize exclusively in Intellectual Property. A multidisciplinary group that is able to assist companies from taking development decisions, contacting providers and collaborators, to the secure launch of a new product. The consulting work also helps companies to identify and protect technical improvements and inventions. This field of practice includes the protection of patents and trademarks, plant varieties, copyright, IP and licensing contracts, unfair competition, technology transfer agreements, trade secret, and other related areas such as the internet and advertising.
Sérgio Mecena - smecena@parquedavida.rj.gov.br Priscilla Palhano - priscilla.palhano@vitalbrazil.rj.gov.br www.vitalbrazil.rj.gov.br The Instituto Vital Brazil (IVB), a research, development and production company belonging to the government of Rio de Janeiro and one of the 20 official laboratories, provides strategic health products to the Brazilian Ministry of Health, like hyperimmune sera and synthetic and biological medicines. In 2010, IVB created the Technological Park of Life which aims to increase biotechnology projects and services. The Institute is part of a state executive group, the Grupo Executivo do Complexo Industrial das Ciências da Vida (Geciv-RJ) that promotes actions to spread the State biotechnology policy and since last year also became a Biotechnology Industry Organization member.
Patricia de Castro Cerqueira Vilela patrícia@invitro.com.br www.invitro.com.br In Vitro Diagnóstica Ltda is a Brazilian company dedicated to the development, manufacturing and distribution of in vitro diagnostic tests, reagents and equipment for clinical laboratories. In Vitro Diagnóstica has a net of distributors around Brazil. We are a certificated company for ANVISA`s GMP and ANVISA`s Good Distribution and Storage Practices.
18
Sheyla Máximo diretoria@jhs.med.br www.jhs.med.br JHS is a biotechnology company that develops and offers differentiated medicine and destistry products in order to restore and improve the human health and well-being. Our products have been marketed since 1999 for orthopedics, neurosurgery, otorhinolaryngology, oral and maxillofacial surgery, and destistry procedures with positive results and high index of approval by the health practitioners.
João Luis Vianna, M.D. joao.vianna@kasznarleonardos.com www.kasznarleonardos.com With offices in Rio de Janeiro, São Paulo and Porto Alegre, Kasznar Leonardos Intellectual Property (or simply Kas-znar) provides Brazilian and foreign companies with a wide range of technical and judicial services in IP areas, such as trademarks, patents, copyrights, computer and software rights, unfair competition, trade secrets, litigation and dispute resolution, technology transfer, regulatory healthcare law and protection of plant varieties, among others.
Katia Torres katia@linhagen.com.br www.linhagen.com.br LINHAGEN is a private held Brazilian company specialized in the development of molecular tools for horses, cattle and ovines. The company provides services on genetic identification, molecular diagnostics and meat traceability. We seek companies interested in technological and financial partnerships.
Otávia Caballero ocaballero@orygen.com.br www.orygen.com.br An innovative Brazilian biotechnology company formed by a joint venture between Biolab Sanus and Eurofarma, led by Dr. Andrew Simpson, former Scientific Director of the Ludwig Institute for Cancer Research. As a result of a stimulus by the Brazilian government, Orygen will initially focus on the manufacture of biosimilar monoclonal antibodies, while it starts the development of its own proprietary biotherapeutic products. The total investment in creating the company and establishing an industrial scale production plant will be approximately $250M. 19
Eduardo Pontes eduardo.pontes@ourofino.com www.ourofino.com Ourofino is the largest Brazilian animal health company with a commercial presence throughout Latin America. The company was established in 1987 in Brazil and currently has more than 1400 employees, three research centers in Brazil, state-of-the-art manufacturing facilities, a solid customer base and one of the largest sales forces in the region. Ourofino also completed an IPO in 2014, which represented the start of a new period of growth and expansion. Ourofino develops, manufactures and commercializes a wide range of animal health products, including medicines, vaccines, anti-parasitic drugs, reproductive hormones, feed additives and supplements for livestock and companion animals. We are actively looking for partnerships that can help us create value to our customers and shareholders by launching new and innovative products for animal health or by expanding our commercial reach in other regions. We believe we are in a great position to bring new technologies to our markets and generate outstanding results, benefiting our partners and customers.
Igor Proscurshim igor.proscurshim@receptabiopharma.com.br www.receptabiopharma.com.br Recepta Biopharma is a Brazilian biotechnology company focused on the research and development of innovative products for cancer therapy. Recepta’s portfolio includes five monoclonal antibodies (mAbs), two peptides and two checkpoint modulating mAbs (CPMs), that are in different stages of development. The checkpoint modulators result from a partnership between Recepta, 4Antibody, and the Ludwig Institute for Cancer Research. In 2016, Recepta will be conducting three first-in-human Phase I studies for three different products including our checkpoint modulators. This will initiate a new era of oncology development in Brazil. Recepta has an extremely aggressive development plan and is working with many institutions in Brazil to make that happen. Hopefully these efforts will result in new, and accessible, life-saving therapies for Brazilian patients.
20
Eduardo Cicconi
eduardocicconi@fipase.org.br www.fipase.org.br
SUPERA, managed by FIPASE (legal entity), develops and strengthens the local industry to expand national and internationally, attracts technology based companies and stimulates the creation of new ones. Has actually 40 companies (between the incubator and business center) and is preparing 126 plots (totalizing 150.000 sq meters) for companies’ installation. Also participates in the governance of the two clusters: the clusters of Health and Software, which together sum 300 companies. It has a laboratories’ complex where the companies can test and improve their products according to international normatives. SUPERA is the most significant entrepreneur institution of the region. Below are the companies hosted at SUPERA Park from the biotech sector: www.nanophoton.com.br
www.inventbitech.com.br
www.veritaslifesciences.com.br
www.narcissus.com.br
www.nanophoton.com.br
www.veritaslifesciences.com.br
www.inventbitech.com.br
www.narcissus.com.br
eloisakronka@gmail.com
eloisakronka@gmail.com dl@brprocess.com
dl@brprocess.com
Sandra Pereira Faça sandra.faca@veritasls.com.br www.veritasls.com.br VERITAS LIFE SCIENCES is a Brazilian biotechnology company focused on supplying the R&D market demand for new, licensable and preclinical validated molecules to feed the product pipeline of organizations working on human health. Our pipeline contains currently a new monoclonal antibody for cancer theranostic in preclinical studies. Our antibody blocks tumor growth and metastasis based on in vitro models of ovarian, lung and other cancers. And also recognize circulating cancer cells and tumors (TMA). We are in the process of testing in ovarian and breast tumor xenograft animal models (USA CRO contracted). None of the available or in clinical development monoclonal antibodies is based on our target. Our R&D pipeline also includes novel antibacterial agents against tuberculosis infection, ending discovery phase.
Kátia Torres katia@visiongen.com.br www.visiongen.com.br The company is also a Lab Service Provider for International Genomic Companies. We have technology license agre - ement with National and International Companies. Through these agreements International Companies can offer their services and products in the country without facing Brazilian and international legislation regarding shipment of biological samples. 21
Brazilian Pavilion booth #1407 sponsored by
Be well
23
Coordinated by
Supported by